nodes	percent_of_prediction	percent_of_DWPC	metapath
Nefazodone—CYP3A7—Ifosfamide—testicular cancer	0.108	0.177	CbGbCtD
Nefazodone—CYP3A7-CYP3A51P—Ifosfamide—testicular cancer	0.108	0.177	CbGbCtD
Nefazodone—CYP3A5—Ifosfamide—testicular cancer	0.0809	0.133	CbGbCtD
Nefazodone—ADRA1B—vas deferens—testicular cancer	0.0486	0.646	CbGeAlD
Nefazodone—ABCB1—Dactinomycin—testicular cancer	0.0446	0.0733	CbGbCtD
Nefazodone—CYP3A5—Etoposide—testicular cancer	0.0387	0.0635	CbGbCtD
Nefazodone—CYP3A4—Ifosfamide—testicular cancer	0.0316	0.0518	CbGbCtD
Nefazodone—ABCB1—Vinblastine—testicular cancer	0.0279	0.0459	CbGbCtD
Nefazodone—CYP2D6—Vinblastine—testicular cancer	0.0263	0.0433	CbGbCtD
Nefazodone—ABCB1—Cisplatin—testicular cancer	0.0256	0.0421	CbGbCtD
Nefazodone—ABCB1—Etoposide—testicular cancer	0.0252	0.0414	CbGbCtD
Nefazodone—ABCB1—Doxorubicin—testicular cancer	0.0172	0.0282	CbGbCtD
Nefazodone—CYP3A4—Vinblastine—testicular cancer	0.0167	0.0275	CbGbCtD
Nefazodone—ABCB1—Methotrexate—testicular cancer	0.0166	0.0273	CbGbCtD
Nefazodone—CYP2D6—Doxorubicin—testicular cancer	0.0162	0.0266	CbGbCtD
Nefazodone—CYP3A4—Etoposide—testicular cancer	0.0151	0.0248	CbGbCtD
Nefazodone—CYP3A4—Doxorubicin—testicular cancer	0.0103	0.0169	CbGbCtD
Nefazodone—HTR2A—vein—testicular cancer	0.0075	0.0996	CbGeAlD
Nefazodone—SLC6A2—gonad—testicular cancer	0.0016	0.0213	CbGeAlD
Nefazodone—ADRA2A—seminal vesicle—testicular cancer	0.00157	0.0208	CbGeAlD
Nefazodone—SLC6A3—testis—testicular cancer	0.00143	0.019	CbGeAlD
Nefazodone—HTR2A—embryo—testicular cancer	0.00142	0.0189	CbGeAlD
Nefazodone—SLC6A2—testis—testicular cancer	0.00116	0.0153	CbGeAlD
Nefazodone—ADRA2A—gonad—testicular cancer	0.00113	0.0151	CbGeAlD
Nefazodone—CYP3A5—female gonad—testicular cancer	0.000966	0.0128	CbGeAlD
Nefazodone—HTR2A—gonad—testicular cancer	0.000963	0.0128	CbGeAlD
Nefazodone—ABCB1—embryo—testicular cancer	0.00093	0.0124	CbGeAlD
Nefazodone—ADRA2A—female gonad—testicular cancer	0.000921	0.0122	CbGeAlD
Nefazodone—ABCB1—seminal vesicle—testicular cancer	0.000874	0.0116	CbGeAlD
Nefazodone—SLC6A2—lymph node—testicular cancer	0.000837	0.0111	CbGeAlD
Nefazodone—ADRA2A—testis—testicular cancer	0.000817	0.0108	CbGeAlD
Nefazodone—CYP2D6—female gonad—testicular cancer	0.000713	0.00948	CbGeAlD
Nefazodone—HTR2A—testis—testicular cancer	0.000694	0.00922	CbGeAlD
Nefazodone—CYP2D6—testis—testicular cancer	0.000633	0.0084	CbGeAlD
Nefazodone—ABCB1—gonad—testicular cancer	0.000631	0.00839	CbGeAlD
Nefazodone—ADRA2A—lymph node—testicular cancer	0.000592	0.00786	CbGeAlD
Nefazodone—ABCB1—female gonad—testicular cancer	0.000513	0.00682	CbGeAlD
Nefazodone—ABCB1—testis—testicular cancer	0.000455	0.00605	CbGeAlD
Nefazodone—ABCB1—lymph node—testicular cancer	0.00033	0.00438	CbGeAlD
Nefazodone—Rash—Dactinomycin—testicular cancer	0.000253	0.0008	CcSEcCtD
Nefazodone—Decreased appetite—Etoposide—testicular cancer	0.000252	0.000798	CcSEcCtD
Nefazodone—Diarrhoea—Ifosfamide—testicular cancer	0.000251	0.000796	CcSEcCtD
Nefazodone—Body temperature increased—Cisplatin—testicular cancer	0.00025	0.000792	CcSEcCtD
Nefazodone—Stomatitis—Epirubicin—testicular cancer	0.000249	0.000787	CcSEcCtD
Nefazodone—Pain—Etoposide—testicular cancer	0.000248	0.000785	CcSEcCtD
Nefazodone—Constipation—Etoposide—testicular cancer	0.000248	0.000785	CcSEcCtD
Nefazodone—Urinary tract infection—Epirubicin—testicular cancer	0.000248	0.000785	CcSEcCtD
Nefazodone—Conjunctivitis—Epirubicin—testicular cancer	0.000248	0.000785	CcSEcCtD
Nefazodone—Dysuria—Doxorubicin—testicular cancer	0.000248	0.000783	CcSEcCtD
Nefazodone—Haemoglobin—Methotrexate—testicular cancer	0.000246	0.000778	CcSEcCtD
Nefazodone—Haemorrhage—Methotrexate—testicular cancer	0.000245	0.000774	CcSEcCtD
Nefazodone—Hepatitis—Methotrexate—testicular cancer	0.000245	0.000774	CcSEcCtD
Nefazodone—Sweating—Epirubicin—testicular cancer	0.000245	0.000774	CcSEcCtD
Nefazodone—Pollakiuria—Doxorubicin—testicular cancer	0.000245	0.000774	CcSEcCtD
Nefazodone—Haematuria—Epirubicin—testicular cancer	0.000243	0.00077	CcSEcCtD
Nefazodone—Dizziness—Ifosfamide—testicular cancer	0.000243	0.000769	CcSEcCtD
Nefazodone—Pharyngitis—Methotrexate—testicular cancer	0.000243	0.000768	CcSEcCtD
Nefazodone—Photosensitivity reaction—Doxorubicin—testicular cancer	0.000242	0.000765	CcSEcCtD
Nefazodone—Weight increased—Doxorubicin—testicular cancer	0.000241	0.000762	CcSEcCtD
Nefazodone—Epistaxis—Epirubicin—testicular cancer	0.000241	0.000761	CcSEcCtD
Nefazodone—Weight decreased—Doxorubicin—testicular cancer	0.000239	0.000758	CcSEcCtD
Nefazodone—Sinusitis—Epirubicin—testicular cancer	0.000239	0.000757	CcSEcCtD
Nefazodone—Feeling abnormal—Etoposide—testicular cancer	0.000239	0.000757	CcSEcCtD
Nefazodone—Nausea—Dactinomycin—testicular cancer	0.000238	0.000754	CcSEcCtD
Nefazodone—Pneumonia—Doxorubicin—testicular cancer	0.000237	0.000751	CcSEcCtD
Nefazodone—Gastrointestinal pain—Etoposide—testicular cancer	0.000237	0.000751	CcSEcCtD
Nefazodone—Visual impairment—Methotrexate—testicular cancer	0.000236	0.000746	CcSEcCtD
Nefazodone—Stevens-Johnson syndrome—Doxorubicin—testicular cancer	0.000234	0.00074	CcSEcCtD
Nefazodone—Vomiting—Ifosfamide—testicular cancer	0.000234	0.000739	CcSEcCtD
Nefazodone—Hypersensitivity—Cisplatin—testicular cancer	0.000233	0.000739	CcSEcCtD
Nefazodone—Bradycardia—Epirubicin—testicular cancer	0.000233	0.000738	CcSEcCtD
Nefazodone—Rash—Ifosfamide—testicular cancer	0.000232	0.000733	CcSEcCtD
Nefazodone—Dermatitis—Ifosfamide—testicular cancer	0.000231	0.000732	CcSEcCtD
Nefazodone—Erythema multiforme—Methotrexate—testicular cancer	0.000231	0.000732	CcSEcCtD
Nefazodone—Urticaria—Etoposide—testicular cancer	0.000231	0.00073	CcSEcCtD
Nefazodone—Haemoglobin—Epirubicin—testicular cancer	0.00023	0.000728	CcSEcCtD
Nefazodone—Stomatitis—Doxorubicin—testicular cancer	0.00023	0.000728	CcSEcCtD
Nefazodone—Rhinitis—Epirubicin—testicular cancer	0.00023	0.000726	CcSEcCtD
Nefazodone—Body temperature increased—Etoposide—testicular cancer	0.000229	0.000726	CcSEcCtD
Nefazodone—Abdominal pain—Etoposide—testicular cancer	0.000229	0.000726	CcSEcCtD
Nefazodone—Urinary tract infection—Doxorubicin—testicular cancer	0.000229	0.000726	CcSEcCtD
Nefazodone—Conjunctivitis—Doxorubicin—testicular cancer	0.000229	0.000726	CcSEcCtD
Nefazodone—Haemorrhage—Epirubicin—testicular cancer	0.000229	0.000725	CcSEcCtD
Nefazodone—Hepatitis—Epirubicin—testicular cancer	0.000229	0.000725	CcSEcCtD
Nefazodone—Tinnitus—Methotrexate—testicular cancer	0.000228	0.000722	CcSEcCtD
Nefazodone—Hypoaesthesia—Epirubicin—testicular cancer	0.000228	0.000721	CcSEcCtD
Nefazodone—Asthenia—Cisplatin—testicular cancer	0.000227	0.000719	CcSEcCtD
Nefazodone—Pharyngitis—Epirubicin—testicular cancer	0.000227	0.000719	CcSEcCtD
Nefazodone—Sweating—Doxorubicin—testicular cancer	0.000226	0.000716	CcSEcCtD
Nefazodone—Oedema peripheral—Epirubicin—testicular cancer	0.000226	0.000714	CcSEcCtD
Nefazodone—Haematuria—Doxorubicin—testicular cancer	0.000225	0.000712	CcSEcCtD
Nefazodone—Epistaxis—Doxorubicin—testicular cancer	0.000223	0.000704	CcSEcCtD
Nefazodone—Sinusitis—Doxorubicin—testicular cancer	0.000221	0.000701	CcSEcCtD
Nefazodone—Visual impairment—Epirubicin—testicular cancer	0.000221	0.000698	CcSEcCtD
Nefazodone—Chills—Methotrexate—testicular cancer	0.00022	0.000695	CcSEcCtD
Nefazodone—Nausea—Ifosfamide—testicular cancer	0.000218	0.000691	CcSEcCtD
Nefazodone—Diarrhoea—Cisplatin—testicular cancer	0.000217	0.000686	CcSEcCtD
Nefazodone—Erythema multiforme—Epirubicin—testicular cancer	0.000217	0.000685	CcSEcCtD
Nefazodone—Alopecia—Methotrexate—testicular cancer	0.000216	0.000684	CcSEcCtD
Nefazodone—Bradycardia—Doxorubicin—testicular cancer	0.000216	0.000683	CcSEcCtD
Nefazodone—Hypersensitivity—Etoposide—testicular cancer	0.000214	0.000677	CcSEcCtD
Nefazodone—Tinnitus—Epirubicin—testicular cancer	0.000214	0.000676	CcSEcCtD
Nefazodone—Haemoglobin—Doxorubicin—testicular cancer	0.000213	0.000674	CcSEcCtD
Nefazodone—Flushing—Epirubicin—testicular cancer	0.000213	0.000672	CcSEcCtD
Nefazodone—Rhinitis—Doxorubicin—testicular cancer	0.000212	0.000672	CcSEcCtD
Nefazodone—Haemorrhage—Doxorubicin—testicular cancer	0.000212	0.00067	CcSEcCtD
Nefazodone—Hepatitis—Doxorubicin—testicular cancer	0.000212	0.00067	CcSEcCtD
Nefazodone—Hypoaesthesia—Doxorubicin—testicular cancer	0.000211	0.000667	CcSEcCtD
Nefazodone—Pharyngitis—Doxorubicin—testicular cancer	0.00021	0.000665	CcSEcCtD
Nefazodone—Oedema peripheral—Doxorubicin—testicular cancer	0.000209	0.00066	CcSEcCtD
Nefazodone—Dysgeusia—Methotrexate—testicular cancer	0.000209	0.00066	CcSEcCtD
Nefazodone—Asthenia—Etoposide—testicular cancer	0.000208	0.000659	CcSEcCtD
Nefazodone—Back pain—Methotrexate—testicular cancer	0.000206	0.000652	CcSEcCtD
Nefazodone—Chills—Epirubicin—testicular cancer	0.000205	0.00065	CcSEcCtD
Nefazodone—Pruritus—Etoposide—testicular cancer	0.000205	0.00065	CcSEcCtD
Nefazodone—Visual impairment—Doxorubicin—testicular cancer	0.000204	0.000646	CcSEcCtD
Nefazodone—Alopecia—Epirubicin—testicular cancer	0.000202	0.00064	CcSEcCtD
Nefazodone—Vomiting—Cisplatin—testicular cancer	0.000201	0.000637	CcSEcCtD
Nefazodone—Vision blurred—Methotrexate—testicular cancer	0.000201	0.000635	CcSEcCtD
Nefazodone—Erythema multiforme—Doxorubicin—testicular cancer	0.0002	0.000634	CcSEcCtD
Nefazodone—Rash—Cisplatin—testicular cancer	0.0002	0.000632	CcSEcCtD
Nefazodone—Dermatitis—Cisplatin—testicular cancer	0.0002	0.000631	CcSEcCtD
Nefazodone—Diarrhoea—Etoposide—testicular cancer	0.000199	0.000628	CcSEcCtD
Nefazodone—Ill-defined disorder—Methotrexate—testicular cancer	0.000198	0.000625	CcSEcCtD
Nefazodone—Tinnitus—Doxorubicin—testicular cancer	0.000198	0.000625	CcSEcCtD
Nefazodone—Anaemia—Methotrexate—testicular cancer	0.000197	0.000623	CcSEcCtD
Nefazodone—Flushing—Doxorubicin—testicular cancer	0.000197	0.000622	CcSEcCtD
Nefazodone—Flatulence—Epirubicin—testicular cancer	0.000196	0.000622	CcSEcCtD
Nefazodone—Dysgeusia—Epirubicin—testicular cancer	0.000195	0.000618	CcSEcCtD
Nefazodone—Back pain—Epirubicin—testicular cancer	0.000193	0.00061	CcSEcCtD
Nefazodone—Malaise—Methotrexate—testicular cancer	0.000192	0.000608	CcSEcCtD
Nefazodone—Dizziness—Etoposide—testicular cancer	0.000192	0.000607	CcSEcCtD
Nefazodone—Muscle spasms—Epirubicin—testicular cancer	0.000192	0.000606	CcSEcCtD
Nefazodone—Vertigo—Methotrexate—testicular cancer	0.000191	0.000606	CcSEcCtD
Nefazodone—Leukopenia—Methotrexate—testicular cancer	0.000191	0.000603	CcSEcCtD
Nefazodone—Chills—Doxorubicin—testicular cancer	0.00019	0.000602	CcSEcCtD
Nefazodone—Nausea—Cisplatin—testicular cancer	0.000188	0.000595	CcSEcCtD
Nefazodone—Vision blurred—Epirubicin—testicular cancer	0.000188	0.000594	CcSEcCtD
Nefazodone—Alopecia—Doxorubicin—testicular cancer	0.000187	0.000592	CcSEcCtD
Nefazodone—Cough—Methotrexate—testicular cancer	0.000186	0.000588	CcSEcCtD
Nefazodone—Ill-defined disorder—Epirubicin—testicular cancer	0.000185	0.000585	CcSEcCtD
Nefazodone—Convulsion—Methotrexate—testicular cancer	0.000185	0.000584	CcSEcCtD
Nefazodone—Vomiting—Etoposide—testicular cancer	0.000185	0.000584	CcSEcCtD
Nefazodone—Anaemia—Epirubicin—testicular cancer	0.000184	0.000583	CcSEcCtD
Nefazodone—Agitation—Epirubicin—testicular cancer	0.000183	0.00058	CcSEcCtD
Nefazodone—Rash—Etoposide—testicular cancer	0.000183	0.000579	CcSEcCtD
Nefazodone—Dermatitis—Etoposide—testicular cancer	0.000183	0.000578	CcSEcCtD
Nefazodone—Headache—Etoposide—testicular cancer	0.000182	0.000575	CcSEcCtD
Nefazodone—Flatulence—Doxorubicin—testicular cancer	0.000182	0.000575	CcSEcCtD
Nefazodone—Arthralgia—Methotrexate—testicular cancer	0.000181	0.000574	CcSEcCtD
Nefazodone—Chest pain—Methotrexate—testicular cancer	0.000181	0.000574	CcSEcCtD
Nefazodone—Myalgia—Methotrexate—testicular cancer	0.000181	0.000574	CcSEcCtD
Nefazodone—Dysgeusia—Doxorubicin—testicular cancer	0.000181	0.000572	CcSEcCtD
Nefazodone—Malaise—Epirubicin—testicular cancer	0.00018	0.000569	CcSEcCtD
Nefazodone—Discomfort—Methotrexate—testicular cancer	0.000179	0.000567	CcSEcCtD
Nefazodone—Vertigo—Epirubicin—testicular cancer	0.000179	0.000567	CcSEcCtD
Nefazodone—Syncope—Epirubicin—testicular cancer	0.000179	0.000566	CcSEcCtD
Nefazodone—Leukopenia—Epirubicin—testicular cancer	0.000178	0.000565	CcSEcCtD
Nefazodone—Back pain—Doxorubicin—testicular cancer	0.000178	0.000565	CcSEcCtD
Nefazodone—Muscle spasms—Doxorubicin—testicular cancer	0.000177	0.000561	CcSEcCtD
Nefazodone—Palpitations—Epirubicin—testicular cancer	0.000176	0.000557	CcSEcCtD
Nefazodone—Confusional state—Methotrexate—testicular cancer	0.000175	0.000555	CcSEcCtD
Nefazodone—Loss of consciousness—Epirubicin—testicular cancer	0.000175	0.000554	CcSEcCtD
Nefazodone—Cough—Epirubicin—testicular cancer	0.000174	0.00055	CcSEcCtD
Nefazodone—Anaphylactic shock—Methotrexate—testicular cancer	0.000174	0.00055	CcSEcCtD
Nefazodone—Vision blurred—Doxorubicin—testicular cancer	0.000174	0.00055	CcSEcCtD
Nefazodone—Convulsion—Epirubicin—testicular cancer	0.000173	0.000546	CcSEcCtD
Nefazodone—Infection—Methotrexate—testicular cancer	0.000173	0.000546	CcSEcCtD
Nefazodone—Nausea—Etoposide—testicular cancer	0.000172	0.000545	CcSEcCtD
Nefazodone—Hypertension—Epirubicin—testicular cancer	0.000172	0.000545	CcSEcCtD
Nefazodone—Ill-defined disorder—Doxorubicin—testicular cancer	0.000171	0.000542	CcSEcCtD
Nefazodone—Anaemia—Doxorubicin—testicular cancer	0.00017	0.000539	CcSEcCtD
Nefazodone—Thrombocytopenia—Methotrexate—testicular cancer	0.00017	0.000539	CcSEcCtD
Nefazodone—Arthralgia—Epirubicin—testicular cancer	0.00017	0.000537	CcSEcCtD
Nefazodone—Chest pain—Epirubicin—testicular cancer	0.00017	0.000537	CcSEcCtD
Nefazodone—Myalgia—Epirubicin—testicular cancer	0.00017	0.000537	CcSEcCtD
Nefazodone—Agitation—Doxorubicin—testicular cancer	0.00017	0.000536	CcSEcCtD
Nefazodone—Anxiety—Epirubicin—testicular cancer	0.000169	0.000535	CcSEcCtD
Nefazodone—Hyperhidrosis—Methotrexate—testicular cancer	0.000168	0.000532	CcSEcCtD
Nefazodone—Discomfort—Epirubicin—testicular cancer	0.000168	0.000531	CcSEcCtD
Nefazodone—Malaise—Doxorubicin—testicular cancer	0.000166	0.000526	CcSEcCtD
Nefazodone—Dry mouth—Epirubicin—testicular cancer	0.000166	0.000525	CcSEcCtD
Nefazodone—Vertigo—Doxorubicin—testicular cancer	0.000166	0.000524	CcSEcCtD
Nefazodone—Anorexia—Methotrexate—testicular cancer	0.000166	0.000524	CcSEcCtD
Nefazodone—Syncope—Doxorubicin—testicular cancer	0.000165	0.000523	CcSEcCtD
Nefazodone—Leukopenia—Doxorubicin—testicular cancer	0.000165	0.000522	CcSEcCtD
Nefazodone—Confusional state—Epirubicin—testicular cancer	0.000164	0.000519	CcSEcCtD
Nefazodone—Palpitations—Doxorubicin—testicular cancer	0.000163	0.000516	CcSEcCtD
Nefazodone—Anaphylactic shock—Epirubicin—testicular cancer	0.000163	0.000515	CcSEcCtD
Nefazodone—Oedema—Epirubicin—testicular cancer	0.000163	0.000515	CcSEcCtD
Nefazodone—Hypotension—Methotrexate—testicular cancer	0.000162	0.000514	CcSEcCtD
Nefazodone—Loss of consciousness—Doxorubicin—testicular cancer	0.000162	0.000513	CcSEcCtD
Nefazodone—Infection—Epirubicin—testicular cancer	0.000162	0.000511	CcSEcCtD
Nefazodone—Cough—Doxorubicin—testicular cancer	0.000161	0.000509	CcSEcCtD
Nefazodone—Shock—Epirubicin—testicular cancer	0.00016	0.000506	CcSEcCtD
Nefazodone—Convulsion—Doxorubicin—testicular cancer	0.00016	0.000506	CcSEcCtD
Nefazodone—Thrombocytopenia—Epirubicin—testicular cancer	0.000159	0.000504	CcSEcCtD
Nefazodone—Hypertension—Doxorubicin—testicular cancer	0.000159	0.000504	CcSEcCtD
Nefazodone—Tachycardia—Epirubicin—testicular cancer	0.000159	0.000502	CcSEcCtD
Nefazodone—Musculoskeletal discomfort—Methotrexate—testicular cancer	0.000158	0.000501	CcSEcCtD
Nefazodone—Hyperhidrosis—Epirubicin—testicular cancer	0.000157	0.000498	CcSEcCtD
Nefazodone—Insomnia—Methotrexate—testicular cancer	0.000157	0.000498	CcSEcCtD
Nefazodone—Chest pain—Doxorubicin—testicular cancer	0.000157	0.000497	CcSEcCtD
Nefazodone—Arthralgia—Doxorubicin—testicular cancer	0.000157	0.000497	CcSEcCtD
Nefazodone—Myalgia—Doxorubicin—testicular cancer	0.000157	0.000497	CcSEcCtD
Nefazodone—Anxiety—Doxorubicin—testicular cancer	0.000156	0.000495	CcSEcCtD
Nefazodone—Paraesthesia—Methotrexate—testicular cancer	0.000156	0.000494	CcSEcCtD
Nefazodone—Discomfort—Doxorubicin—testicular cancer	0.000155	0.000491	CcSEcCtD
Nefazodone—Anorexia—Epirubicin—testicular cancer	0.000155	0.000491	CcSEcCtD
Nefazodone—Dyspnoea—Methotrexate—testicular cancer	0.000155	0.00049	CcSEcCtD
Nefazodone—Somnolence—Methotrexate—testicular cancer	0.000155	0.000489	CcSEcCtD
Nefazodone—Dry mouth—Doxorubicin—testicular cancer	0.000154	0.000486	CcSEcCtD
Nefazodone—Dyspepsia—Methotrexate—testicular cancer	0.000153	0.000484	CcSEcCtD
Nefazodone—Hypotension—Epirubicin—testicular cancer	0.000152	0.000481	CcSEcCtD
Nefazodone—Confusional state—Doxorubicin—testicular cancer	0.000152	0.00048	CcSEcCtD
Nefazodone—Decreased appetite—Methotrexate—testicular cancer	0.000151	0.000478	CcSEcCtD
Nefazodone—Anaphylactic shock—Doxorubicin—testicular cancer	0.000151	0.000476	CcSEcCtD
Nefazodone—Oedema—Doxorubicin—testicular cancer	0.000151	0.000476	CcSEcCtD
Nefazodone—Infection—Doxorubicin—testicular cancer	0.00015	0.000473	CcSEcCtD
Nefazodone—Pain—Methotrexate—testicular cancer	0.000149	0.00047	CcSEcCtD
Nefazodone—Musculoskeletal discomfort—Epirubicin—testicular cancer	0.000148	0.000469	CcSEcCtD
Nefazodone—Shock—Doxorubicin—testicular cancer	0.000148	0.000469	CcSEcCtD
Nefazodone—Thrombocytopenia—Doxorubicin—testicular cancer	0.000147	0.000466	CcSEcCtD
Nefazodone—Insomnia—Epirubicin—testicular cancer	0.000147	0.000466	CcSEcCtD
Nefazodone—Tachycardia—Doxorubicin—testicular cancer	0.000147	0.000465	CcSEcCtD
Nefazodone—Paraesthesia—Epirubicin—testicular cancer	0.000146	0.000462	CcSEcCtD
Nefazodone—Hyperhidrosis—Doxorubicin—testicular cancer	0.000146	0.00046	CcSEcCtD
Nefazodone—Dyspnoea—Epirubicin—testicular cancer	0.000145	0.000459	CcSEcCtD
Nefazodone—Somnolence—Epirubicin—testicular cancer	0.000145	0.000458	CcSEcCtD
Nefazodone—Anorexia—Doxorubicin—testicular cancer	0.000143	0.000454	CcSEcCtD
Nefazodone—Feeling abnormal—Methotrexate—testicular cancer	0.000143	0.000453	CcSEcCtD
Nefazodone—Dyspepsia—Epirubicin—testicular cancer	0.000143	0.000453	CcSEcCtD
Nefazodone—Gastrointestinal pain—Methotrexate—testicular cancer	0.000142	0.00045	CcSEcCtD
Nefazodone—Decreased appetite—Epirubicin—testicular cancer	0.000141	0.000447	CcSEcCtD
Nefazodone—Hypotension—Doxorubicin—testicular cancer	0.000141	0.000445	CcSEcCtD
Nefazodone—Constipation—Epirubicin—testicular cancer	0.000139	0.00044	CcSEcCtD
Nefazodone—Pain—Epirubicin—testicular cancer	0.000139	0.00044	CcSEcCtD
Nefazodone—Urticaria—Methotrexate—testicular cancer	0.000138	0.000437	CcSEcCtD
Nefazodone—Abdominal pain—Methotrexate—testicular cancer	0.000137	0.000435	CcSEcCtD
Nefazodone—Body temperature increased—Methotrexate—testicular cancer	0.000137	0.000435	CcSEcCtD
Nefazodone—Musculoskeletal discomfort—Doxorubicin—testicular cancer	0.000137	0.000434	CcSEcCtD
Nefazodone—Insomnia—Doxorubicin—testicular cancer	0.000136	0.000431	CcSEcCtD
Nefazodone—Paraesthesia—Doxorubicin—testicular cancer	0.000135	0.000428	CcSEcCtD
Nefazodone—Dyspnoea—Doxorubicin—testicular cancer	0.000134	0.000425	CcSEcCtD
Nefazodone—Feeling abnormal—Epirubicin—testicular cancer	0.000134	0.000424	CcSEcCtD
Nefazodone—Somnolence—Doxorubicin—testicular cancer	0.000134	0.000423	CcSEcCtD
Nefazodone—Gastrointestinal pain—Epirubicin—testicular cancer	0.000133	0.000421	CcSEcCtD
Nefazodone—Dyspepsia—Doxorubicin—testicular cancer	0.000133	0.000419	CcSEcCtD
Nefazodone—Decreased appetite—Doxorubicin—testicular cancer	0.000131	0.000414	CcSEcCtD
Nefazodone—Urticaria—Epirubicin—testicular cancer	0.000129	0.000409	CcSEcCtD
Nefazodone—Pain—Doxorubicin—testicular cancer	0.000129	0.000407	CcSEcCtD
Nefazodone—Constipation—Doxorubicin—testicular cancer	0.000129	0.000407	CcSEcCtD
Nefazodone—Abdominal pain—Epirubicin—testicular cancer	0.000129	0.000407	CcSEcCtD
Nefazodone—Body temperature increased—Epirubicin—testicular cancer	0.000129	0.000407	CcSEcCtD
Nefazodone—Hypersensitivity—Methotrexate—testicular cancer	0.000128	0.000405	CcSEcCtD
Nefazodone—Asthenia—Methotrexate—testicular cancer	0.000125	0.000395	CcSEcCtD
Nefazodone—Feeling abnormal—Doxorubicin—testicular cancer	0.000124	0.000393	CcSEcCtD
Nefazodone—Gastrointestinal pain—Doxorubicin—testicular cancer	0.000123	0.000389	CcSEcCtD
Nefazodone—Pruritus—Methotrexate—testicular cancer	0.000123	0.000389	CcSEcCtD
Nefazodone—Hypersensitivity—Epirubicin—testicular cancer	0.00012	0.000379	CcSEcCtD
Nefazodone—Urticaria—Doxorubicin—testicular cancer	0.00012	0.000378	CcSEcCtD
Nefazodone—Abdominal pain—Doxorubicin—testicular cancer	0.000119	0.000377	CcSEcCtD
Nefazodone—Body temperature increased—Doxorubicin—testicular cancer	0.000119	0.000377	CcSEcCtD
Nefazodone—Diarrhoea—Methotrexate—testicular cancer	0.000119	0.000376	CcSEcCtD
Nefazodone—Asthenia—Epirubicin—testicular cancer	0.000117	0.000369	CcSEcCtD
Nefazodone—Pruritus—Epirubicin—testicular cancer	0.000115	0.000364	CcSEcCtD
Nefazodone—Dizziness—Methotrexate—testicular cancer	0.000115	0.000364	CcSEcCtD
Nefazodone—Diarrhoea—Epirubicin—testicular cancer	0.000111	0.000352	CcSEcCtD
Nefazodone—Hypersensitivity—Doxorubicin—testicular cancer	0.000111	0.000351	CcSEcCtD
Nefazodone—Vomiting—Methotrexate—testicular cancer	0.000111	0.00035	CcSEcCtD
Nefazodone—Rash—Methotrexate—testicular cancer	0.00011	0.000347	CcSEcCtD
Nefazodone—Dermatitis—Methotrexate—testicular cancer	0.00011	0.000347	CcSEcCtD
Nefazodone—Headache—Methotrexate—testicular cancer	0.000109	0.000345	CcSEcCtD
Nefazodone—Asthenia—Doxorubicin—testicular cancer	0.000108	0.000342	CcSEcCtD
Nefazodone—Dizziness—Epirubicin—testicular cancer	0.000108	0.00034	CcSEcCtD
Nefazodone—Pruritus—Doxorubicin—testicular cancer	0.000107	0.000337	CcSEcCtD
Nefazodone—Vomiting—Epirubicin—testicular cancer	0.000103	0.000327	CcSEcCtD
Nefazodone—Nausea—Methotrexate—testicular cancer	0.000103	0.000327	CcSEcCtD
Nefazodone—Diarrhoea—Doxorubicin—testicular cancer	0.000103	0.000326	CcSEcCtD
Nefazodone—Rash—Epirubicin—testicular cancer	0.000103	0.000325	CcSEcCtD
Nefazodone—Dermatitis—Epirubicin—testicular cancer	0.000102	0.000324	CcSEcCtD
Nefazodone—Headache—Epirubicin—testicular cancer	0.000102	0.000322	CcSEcCtD
Nefazodone—Dizziness—Doxorubicin—testicular cancer	9.95e-05	0.000315	CcSEcCtD
Nefazodone—Nausea—Epirubicin—testicular cancer	9.66e-05	0.000306	CcSEcCtD
Nefazodone—Vomiting—Doxorubicin—testicular cancer	9.57e-05	0.000303	CcSEcCtD
Nefazodone—Rash—Doxorubicin—testicular cancer	9.49e-05	0.0003	CcSEcCtD
Nefazodone—Dermatitis—Doxorubicin—testicular cancer	9.48e-05	0.0003	CcSEcCtD
Nefazodone—Headache—Doxorubicin—testicular cancer	9.43e-05	0.000298	CcSEcCtD
Nefazodone—Nausea—Doxorubicin—testicular cancer	8.94e-05	0.000283	CcSEcCtD
